产品说明书

PK11000

Print
Chemical Structure| 38275-34-2 同义名 : -
CAS号 : 38275-34-2
货号 : A536947
分子式 : C6H5ClN2O4S
纯度 : 99%
分子量 : 236.633
MDL号 : MFCD00507244
存储条件:

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(443.73 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 25 mg/mL(105.65 mM),配合低频超声助溶

动物实验配方:
生物活性
描述 The tumor suppressor p53 plays a key role in regulating cell cycle arrest, DNA repair, apoptosis, and cell senescence and is inactivated either by mutation or up-regulation of proteins such as MDM2 or MDMX in virtually all human cancers. Cancers with mutant p53 often show increased metastasis, genomic instability, and higher chemoresistance. PK11007, a thiol-modifying compound, exerts antitumor function via reactivating p53. PK11007 increased protein levels of the p53 target genes p21, MDM2, and PUMA in a mostly concentration-dependent manner in NUGC-3 (p53-Y220C), HUH-7 (p53-Y220C) and MKN1 (p53-V143A) cells and also activated the unfolded protein response pathway in a concentration-dependent manner in HUH-7 cells. PK11007 slightly increased caspase 3/7 activity without inducing membrane permeabilization in SW480 (15% increase at 15 μM), SJSA-1 (40% increase at 30 μM), and HCT116 (10% increase at 60 μM) cells, and depleted GSH and increased concentration of ROS[1]. PK11007 was found to induce apoptosis in both a time and concentration-dependent manner in the two p53-mutated triple-negative breast cancer cell lines investigated, HCC1143 and MDA-MB-468, but not in the WT-p53 cell line, MCF-7[2].
作用机制 PK11007 stabilizes p53 in vitro via selective alkylation of two surface-exposed cysteines without compromising its DNA binding activity.
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.23mL

0.85mL

0.42mL

21.13mL

4.23mL

2.11mL

42.26mL

8.45mL

4.23mL

参考文献

[1]Bauer MR, Joerger AC, Fersht AR. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5271-80. doi: 10.1073/pnas.1610421113. Epub 2016 Aug 22. PMID: 27551077; PMCID: PMC5018792.

[2]Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O'Donovan N, O'Connor D, Gallagher WM, Crown J, Fersht AR, Duffy MJ. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett. 2018 Feb 1;414:99-106. doi: 10.1016/j.canlet.2017.09.053. Epub 2017 Oct 22. PMID: 29069577.